MUC1 and ovarian carcinoma: Additionally, the first clinical trial of CAR-NK therapy for solid tumor treatment used MUC-1 CAR-NK cells to target against multiple malignant solid tumors, e.g., glioblastoma, pancreatic, colorectal, breast and ovarian cancer (NCT02839954).